• 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author

RMDA Share Price Performance

ج.م4.30
0.74 (20.79%)
ج.م4.30
0.74 (20.79%)
Price ج.م4.30

RMDA Community Narratives

There are no narratives available yet.

Snowflake Analysis

High growth potential with proven track record.

2 Risks
3 Rewards

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Key Details

ج.م3.6b

Revenue

ج.م1.9b

Cost of Revenue

ج.م1.7b

Gross Profit

ج.م1.3b

Other Expenses

ج.م415.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
0.28
47.13%
11.62%
101.5%
View Full Analysis

About RMDA

Founded
1986
Employees
n/a
CEO
Amr Morsy
WebsiteView website
www.ramedapharma.com

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of products in various therapeutic areas, such as anti-biotics, cardiovascular diseases and gastro-intestinal tract disorders, anti-infectives, alimentary tract and metabolism, genito-urinary system, nervous system, blood forming organs, weight management, and sex hormones. The company was incorporated in 1986 and is based in 6th of October City, Egypt.

Recent RMDA News & Updates

Recent updates

No updates

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Competitors